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Abstract
BACKGROUND: Patients with non-cystic fibrosis bronchiectasis (BE) have frequent exacerbations that are causes 
of significant morbidity and sometimes mortality, and which it is desirable to prevent. 
AIM: We aimed to assess the effects of pleuran on the incidence and duration of exacerbations in patients with BE.
METHODS: A prospective, observational, open-label, and active-controlled study was realized as a comparison of the 
frequency and duration of exacerbations between a group of patients with BE (30 patients, 14 males and 16 females, 
aged 44–72 years) who received a combination supplement containing pleuran 100 mg, Vitamin C 60 mg and zinc 5 
mg over a 3-month period and a group of patients with BE (31 patients, 15 males and 16 females, aged 45–74 years) 
treated over a 3-month period with a combination supplement containing Vitamin C 60 mg and zinc 5 mg. 
RESULTS: Over the study period, altogether 46 exacerbations were documented (19 in the patients receiving 
pleuran and 27 in the patients who did not receive pleuran), nine of which required hospital treatment (four in the 
patients receiving pleuran [21.5%] and five in the patients who did not receive pleuran [18.6%]). The mean number of 
exacerbations over the study period was significantly lower in the patients receiving pleuran (0.6 ± 0.4) as compared 
to the mean number in the patients who did not receive pleuran (0.8 ± 0.3) (p = 0.0297). The mean duration of 
exacerbations, expressed in days, needed for cure or clinical improvement in the patients receiving pleuran (11.2 ± 
1.7 days) was significantly shorter than that of exacerbations in the patients who did not receive pleuran (12.4 ± 1.3 
days) (p = 0.0029). We found significantly lower incidence and significantly shorter duration of exacerbations in the 
patients with BE who received pleuran as compared to their incidence and duration in the patients with BE who did 
not receive pleuran. 
CONCLUSION: Our findings indicated a need for further investigations in this domain to define the possible role of 
pleuran in the prevention of BE exacerbations.
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Introduction
Non-cystic fibrosis bronchiectasis (BE) is a 
chronic disorder of the major airways characterized 
by permanent dilatation and destruction [1]. The origin 
of BE varies, but the presence of microbial infection 
and a persistent inflammatory response are typical 
characteristics of the disease [2], [3]. There is evidence 
for increased incidence as well as increased mortality of 
BE in recent decades in developed countries [4], [5]. The 
reasons for this are not clear, but may be due to improved 
diagnostics of BE; i.e., to increased use of computed 
tomography (CT) in diagnosis of the disease [6].
Patients with BE have frequent exacerbations 
that are a cause of significant morbidity and sometimes 
mortality, which it is desirable to prevent [7]. BE 
exacerbation is defined as a deterioration of three or more 
of the following key symptoms for at least 48 h: cough; 
sputum volume and/or consistency; sputum purulence; 
breathlessness and/or exercise tolerance; fatigue and/or 
malaise; and hemoptysis; or a clinician determines that 
a change in BE treatment is required [8]. The diagnosis 
of a bacterial infection should be established when a 
combination of symptoms exists. A positive sputum 
culture, by itself, does not indicate an exacerbation, as it is 
usually positive in patients with stable disease, but it can be 
helpful in guiding future antibiotic use [9]. An exacerbation 
is classified as severe in the presence of tachypnea, acute 
respiratory failure, exacerbated chronic respiratory failure, 
a significant decline in oxygen saturation of arterial blood 
or respiratory function or hypercapnia, fever of more than 
38°C, and hemoptysis. In addition, an exacerbation is 
classified as very severe in the presence of hemodynamic 
instability, altered mental status, or a need for intensive or 
intermediate care admission [10].
During an exacerbation, there is often a 
proliferation of bacterial pathogens and increased airway 
and systemic inflammation. Treatment with antibiotics 
has been shown to reduce bacterial burden, as well 
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as inflammation. More than 80% of BE exacerbations 
can be treated in an outpatient setting. In the cases of 
positive sputum culture, the antibiotic therapy should 
follow its findings. The empirical choice of antibiotic 
should be based on previous sputum isolates where 
possible, as well as on any local pattern of resistance, 
availability of medication, and patient response. The 
appropriate duration of antibiotic therapy is 14 days. 
Indications for hospital treatment of BE exacerbations 
include respiratory failure with respiratory rate higher 
than 25/min, hypoxic respiratory failure with oxygen 
saturation of arterial blood lower than 92%, hypotension, 
fever of more than 38 °C, patients with Pseudomonas 
aeruginosa resistant to ciprofloxacin, or failure to 
improve after a course of oral antibiotics [8], [9], [11].
Pleuran is an insoluble 1,3/1,6-β-glucan 
from the mushroom Pleurotus ostreatus. A number of 
experimental studies on animal models, as well as a 
number of experimental and clinical studies in humans, 
indicated immunomodulatory properties of pleuran 
based on its effects on immune cells of Peyer’s patches 
in the gut. After oral administration, pleuran comes 
into contact with immune cells of Peyer’s patches that 
express several receptors (e.g., Dectin-1, complement 
receptor-3, and scavenger receptors) capable of 
recognizing β-glucans. On the binding of pleuran to these 
receptors, a cascade of intracellular signaling is initiated, 
which stimulates innate and subsequently adaptive 
immune responses, mainly through the modulation 
of pro-inflammatory and immunoregulatory cytokine 
production (complement components, interleukin-
1α/β, interleukin-6, interleukin-8, interleukin-12, tumor 
necrosis factor-α, and eicosanoids), which improve the 
resistance to invading pathogens. Moreover, pleuran 
possesses many other beneficial biological activities 
useful in the management of inflammatory diseases, for 
example, anti-inflammatory, anti-oxidant, regenerative, 
and anti-infectious activities [12], [13], [14].
The aim of the present study was to assess 
the effects of pleuran on the incidence and duration 
of exacerbations in patients with BE. This study is a 
continuation of our investigation into the effects of pleuran 
on the incidence and severity of bacterial exacerbations 
in chronic obstructive airway diseases, following on from 
a previous study in which the incidence and severity of 
exacerbations were investigated in patients with stable 
chronic obstructive pulmonary disease (COPD) treated 
with pleuran (COPD patients with accompanying BE 
were not included in the study) [15].
Methods
Study design and setting
A prospective, observational, open-label, and 
active-controlled study (a real-life study) was realized 
as a comparison of the frequency and duration of 
exacerbations between a group of patients with BE 
who received a combination supplement containing 
pleuran 100 mg, Vitamin C 60 mg, and zinc 5 mg over a 
3-month period with a group of patients with BE treated 
over a 3-month period with a combination supplement 
containing Vitamin C 60 mg and zinc 5 mg. It was 
performed over the period November 2017–April 2018 
at the Institute for Occupational Health of R. Macedonia, 
Skopje.
Study subjects
The study population included 61 BE patients 
divided into two groups. The first group (Group 1) 
included 30 patients (14 males and 16 females, aged 
44–72 years) who took the combination supplement 
containing pleuran 100 mg, Vitamin C 60 mg, and 
zinc 5 mg once daily over the period of 3 months. 
The second group (Group 2) included 31 BE patients 
(15 males and 16 females, aged 45–74 years) who 
received the combination supplement containing 
Vitamin C 60 mg and zinc 5 mg once daily, matched 
to the first group by sex, age, and smoking status. 
Patients with accompanying COPD from both groups 
took their maintenance treatment for stable disease as 
recommended.
Patients with a history of asthma, lung cancer 
or other significant respiratory disease, as well as 
those unable to complete diary cards, were excluded 
from the study. All study subjects were recruited in the 
stable phase of the disease, i.e., without any evidence 
of exacerbation for at least 3 weeks.
All study subjects were informed about the 
study and their written consent was obtained.
Daily stable respiratory symptoms (baseline 
symptoms), medication use and history of exacerbations 
were noted for all subjects before entering the 
study. All study subjects underwent baseline and 
post-bronchodilator spirometry according to the 
recommendations of European Respiratory Society and 
American Thoracic Society [16]. In addition, in all study 
subjects, a microbiological evaluation of sputum was 
performed in the stable phase of the disease, as well 
as when the exacerbation was diagnosed, according to 
the recommendations [17].
The body mass index (BMI), as a measure of 
body fat based on height and weight as applied to the 
adult population, was determined in all study subjects 
by computer calculation using a BMI calculator [18].
Classification of smoking status was by the World 
Health Organization (WHO) recommendations [19]. 
Passive smoking or exposure to environmental tobacco 
smoke was defined as an exposure to tobacco 
combustion products from smoking by others (at home, 
in the workplace, etc.), i.e., as the presence of at least 
one smoker in the household and/or the workplace [20].
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Diagnosis and assessment of BE
Diagnosis of BE was based on the findings of 
high-resolution CT (HRCT), as it is currently considered 
as the best tool for its diagnosis. According to the 
recommendations, the main diagnostic features for BE 
are the internal diameter of a bronchus wider than its 
adjacent blood vessel, a failure of the bronchi to taper, 
and the visualization of bronchi in the outer 1–2 cm of 
the lung fields [7], [21], [22]. BE was scored in each 
lobe by consensus, using the grading system proposed 
by Smith et al. [23] as follows: 0 if no BE was present; 1 
if less than 25% of the bronchi were bronchiectatic; 2 if 
25–49% of the bronchi were bronchiectatic; 3 if 50–74% 
of the bronchi were bronchiectatic; and 4 if 75% or more 
of the bronchi were bronchiectatic. As previous studies 
have shown that more than 50% of healthy volunteers 
may have at least one dilated bronchus on HRCT, 
only patients with a total BE score of 2 or more were 
considered to have changes consistent with clinically 
significant disease for the study objectives.
Once the diagnosis was established by HRCT 
scanning, patients underwent a range of investigations 
to determine the underlying cause, as well as to 
determine the severity, of the disease [24]. Diagnosis 
and assessment of COPD were made following the 
recommendations of Global Initiative for COPD [25]. 
In addition, following the recommendation of the BE 
severity index (BSI), BE was classified as mild (low BSI 
score), moderate (intermediate BSI score), or severe 
(high BSI score) [26], [27].
Diagnosis and treatment of BE 
exacerbation
BE exacerbations were diagnosed according 
to the criteria from the guidelines mentioned 
above [7], [8], [9]. The antibiotic therapy lasted 14 
days, being etiological or empirical depending on the 
results of sputum culture [9], [10], [11]. The course 
of exacerbation was evaluated as a function of the 
resolution of symptoms, and the treatment was 
considered successful if cure or clinical improvement 
(i.e., return of the symptoms to their baseline severity) 
was achieved.
Data collection (daily diary card)
Data collection was realized following the 
model used by Patel et al. in their study on BE and 
exacerbation indices [28]. All study subjects maintained 
daily diary cards on which they noted the appearance 
or increase in intensity of three or more symptoms 
(cough, sputum volume and/or consistency, sputum 
purulence, breathlessness and or exercise intolerance, 
fatigue and/or malaise, hemoptysis, fever, etc.). A 
member of the study team saw study subjects within 
48 h of the detection of deterioration in symptoms and 
diagnosis was confirmed in each case. Exacerbation 
and its resolution were defined as mentioned above. 
Exacerbation number and their duration were calculated 
for each study subject based on data from diary cards 
for a 3-month period of follow-up.
Statistical analysis
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) 
version 11.0 for Windows. Continuous variables were 
expressed as mean values with standard deviation 
(SD), and the nominal variables as numbers and 
percentages. Analyses of the data included testing 
the differences in prevalence and comparison of the 
means by Chi-square test (or Fisher’s exact test where 
appropriate) and independent-samples t-test. p < 0.05 
was considered statistically significant.
Results
Demographic and other characteristics of the 
study subjects are shown in Table 1.
Table 1: Characteristics of the study subjects
Variable Group1 (n=30) Group 2 (n=31)
M/F ratio 0.9 0.9
Mean age (years) 52.4 ± 6.1 53.1 ± 7.0
Mean BMI (kg/m2) 25.2 ± 2.6 25.5 ± 3.1
Mean duration of BE after diagnosis (years) 9.3 ± 3.1 9.5 ± 3.7
BE etiology
Post-infective 10 (33.3%) 12 (38,7%)
COPD 6 (20.0%) 5 (19.3%)
Not determined 14 (46.6%) 14 (45.1%)
Type of BE
Cylindrical 13 (43.3%) 14 (45.1%)
Varicose 12 (36.6%) 12 (38.7%)
Cystic 5 (16.6%) 5 (16.1%)
Classification of BE severity by the BSI score
Mild 12 (36.6%) 13 (41.9%)
Moderate 13 (43.3%) 13 (41.9%)
Severe 5 (16.6%) 5 (16.1%)
Mean values of spirometric parameters (% pred.)
FVC 77.3  ±  6.8 78.2  ±  8.1
FEV1 54.1  ±  5.6 55.5  ±  4.9
FEV1/FVC ratio 0.70  ±  0.06 0.71  ±  0.09
Positive sputum culture when clinically stable over the past 12 months
Haemophilus influenzae 9 (30.0%) 10 (32.2%)
Moraxella catarrhalis 4 (13.3%) 5 (16.1%)
Streptococcus pneumoniae 3 (10.0%) 3 (9.6%)
Pseudomonas aeruginosa 3 (10.0%) 3 (9.6%)
Other 2 (6.6%) 2 (6.4%)
No bacteria isolated 9 (30.0%) 8 (25.8%)
Long-term treatment of stable BE
Systemic antibiotics 0 (0%) 0 (0%)
Inhaled antibiotics 0 (0%) 0 (0%)
Mucoactive drugs 3 (10.0%) 4 (12.9%)
Number of exacerbations in the past 12 months 2.4  ±  0.2 2.3  ±  0.6
Smoking status
Active smokers 12 (40.0%) 11 (35.4%)
Ex-smokers 10 (33.3%) 11 (35.4%)
Never smoked 8 (26.6%) 9 (29.0%)
Exposed to ETS 13 (43.3%) 15 (48.3%)
Accompanying COPD 6 (20.0%) 5 (19.3%)
Mild 2 (6.6%) 2 (6.4%)
Moderate 2 (6.6%) 2 (6.4%)
Severe 2 (6.6%) 1 (3.2%)
Very severe 0 (0%) 0 (0%)
Numerical data are expressed as mean value ± SD; frequencies as number and percentage of study 
subjects with given variable. M: Male, F: Female, BMI: Body mass index, kg: Kilogram, m: Meter, 
BE: Bronchiectasis, COPD: Chronic obstructive pulmonary disease, BSI: Bronchiectasis severity index, % 
pred.: % of the predicted value, FVC: Forced vital capacity, FEV1: Forced expiratory volume in one second, 
ETS: Environmental tobacco smoke.
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Over the study period, 46 exacerbations were 
documented (19 in Group 1 and 27 in Group 2), nine 
of which required hospital treatment (four in Group 1 
[21.5%] and five in Group 2 [18.6%]).
Positive sputum culture was obtained in 29 
exacerbations (13 in Group 1 and 19 in Group 2) (Table 2).
Table 2: Findings of sputum culture in exacerbations of the 
study subjects from Group 1 and Group 2
Sputum culture Group 1 n=19 (%) Group 2 n=27 (%)
Haemophilus influenzae 6 (31.5) 9 (33.3)
Moraxella catarrhalis 2 (10.5) 2 (7.4)
Streptococcus pneumoniae 2 (10.5) 4 (14.8)
Pseudomonas aeruginosa 3 (15.7) 3 (11.1)
Staphylococcus aureus 1 (5.2) 1 (3.7)
No bacteria isolated 5 (26.3) 8 (29.6)
Frequencies are expressed as number and percentage of study subjects with finding of sputum culture.
In addition, 34 of the 46 exacerbations (73.9%) 
were treated only with systemic antibiotics (14/19 
[73.7%] in Group 1 and 20/27 [74.1%] in Group 2) and 
12 (26.1%) were treated with systemic antibiotics and 
systemic glucocorticoids (5/19 [26.3%] in Group 1 and 
7/27 [25.9%] in Group 2) (Figure 1):
Figure 1: Treatment of exacerbation in study subjects from Group 1 
and Group 2
The mean number of exacerbations over 
the study period was significantly lower in Group1 
(0.6 ± 0.4) as compared to their mean number in Group 
2 (0.8 ± 0.3) (p = 0.0297) (Figure 2):
Figure 2: Mean number of exacerbations in the examined groups 
(p = 0.0297)
The mean duration of exacerbations, expressed 
in days, needed for cure or clinical improvement (i.e., 
complete resolution of symptoms or return of symptoms 
to their baseline severity) in Group 1 (11.2 ± 1.7 days) 
was significantly shorter than the mean duration of 
exacerbations in Group 2 (12.4 ± 1.3 days) (p = 0.0029) 
(Figure 3):
Figure 3: Mean duration of the exacerbations in the examined groups 
(p = 0.0029)
Adverse effects of the medicaments used over 
the study period were not reported by any study subject 
from either examined group, and the treatment was well 
tolerated.
Discussion
BE is a chronic progressive condition resulting 
from infection and inflammation of the airway, leading 
to destruction, and remodeling of the bronchial wall. 
The clinical manifestations of the disease include 
chronic and commonly purulent expectoration, 
multiple exacerbations, and progressive dyspnea. All 
these events cause progressive decline in the lung 
function and impairment of the quality of life of the 
patients [29], [30], [31].
In the present study, we assessed the effects 
of pleuran (1,3/1,6-β–glucan from P. ostreatus) on the 
incidence and duration of exacerbations in patients 
with BE. To the best of our knowledge, the present 
study is the first to investigate the effects of pleuran 
on the prevention of exacerbations in adult patients 
with BE. Examined groups included BE patients 
diagnosed and classified by severity according to the 
recommendations. Study subjects from the examined 
groups had similar demographic characteristics, as well 
as characteristics related to their disease (mean duration 
of the disease after diagnosis, severity, etiology, lung 
function, microbiological findings in the stable phase of 
the disease, accompanying COPD, etc.). We found a 
high prevalence of active and passive smokers in both 
examined groups, which was similar to their prevalence 
registered in our previous studies [15], [32], [33].
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The immunomodulatory properties of pleuran 
and other fungal β-glucans were studied and described 
almost 50 years ago. As mentioned above, many studies 
have reported the ability of pleuran to activate innate 
immunity, with effects also on adaptive immunity, and in 
inducing humoral and cell-mediated immune responses. 
Pleuran was found to increase the antimicrobial activity 
of mononuclear cells and neutrophils and to enhance 
the functional activity of macrophages. There is also 
evidence from experimental studies of its effects against 
tumor. Finally, there is evidence that β-glucans may 
modulate other conditions (cholesterol level, glucose 
tolerance, etc.). [34], [35], [36]. However, the doses of 
pleuran for clinical use in both children and adults, as well 
as the duration of the treatment, are still not well defined. 
Pleuran is an insoluble substance, non-absorbable and 
non-digestible in the gastrointestinal tract, so systemic 
adverse effects would not be expected. In addition, 
according to the results from existing evidence, local 
(gastrointestinal) side effects occurring during the use of 
pleuran are rare and mild [14], [37].
In the present study, we found significantly lower 
incidence of exacerbations, as well as their significantly 
shorter duration in the study subjects receiving pleuran 
as compared to their incidence and duration in those 
who did not receive pleuran. Similar findings were 
obtained in our study on the effects of pleuran on the 
incidence and duration of exacerbations in patients with 
COPD who received the same doses of pleuran over 
the 3-month period [15]. Similar findings were reported 
by several studies that investigated effects of pleuran on 
incidence, duration, and severity of respiratory infections 
in children [38], [39]. In addition, there is evidence of a 
significant effect of pleuran in the reduction of respiratory 
tract infections in athletes [40]. Furthermore, there is 
evidence for a significant effect of pleuran on natural 
killer cell activity during respiratory infection or after 
intensive exercise in athletes [40], [41]. As in the present 
study, local (i.e., gastrointestinal) adverse effects were 
not registered in any cited studies.
The present study must be interpreted within the 
context of its limitations. As in the case of the study on the 
effects of pleuran on the incidence and duration of COPD 
exacerbations, the results should be viewed with caution, 
since the study was neither blinded nor randomized and, 
therefore, can be subject to possible selection bias. On 
the other hand, the study design may be its strength, as 
is documented by other real-life studies. In addition, the 
small number of subjects in the examined groups and the 
short follow-up period could both have certain implications 
on the data obtained and their interpretation.
Conclusion
In a prospective, observational, open-label, and 
active-controlled study including a group of patients with 
BE who received a combination supplement containing 
pleuran 100 mg, Vitamin C 60 mg, and zinc 5 mg over a 
3-month period, we found significantly lower incidence, 
and significantly shorter duration, of exacerbations as 
compared to their incidence and duration in a group 
of patients with BE treated over a 3-month period with 
the combination supplement containing Vitamin C 
60 mg and zinc 5 mg. Further investigations, as well 
as comparisons with other therapeutic modalities, are 
needed to define the position of pleuran regarding the 
prevention of BE exacerbations.
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